Drs Basch and Bonfiglio present an elegant summary of the limitations of the PDR and the lack of awareness of many health professionals about these limitations. As they suggest, optimal therapeutics depends on complete information about the dose-response relationship of medications as well as on individualizing this information to the needs and characteristics of specific patients.
These doctors' faith in private publishers and electronic models is encouraging. There is no doubt that electronic resources have multiplied since Dr Paul Insel and I discussed the potential impact of these resources in our 1996 article on this topic.1
Cohen JS. Pharmaceutical Manufacturer Sponsorship and Drug Information—Reply. Arch Intern Med. 2001;161(21):2626. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: